BiomarkersPub Date : 2024-12-01Epub Date: 2024-11-22DOI: 10.1080/1354750X.2024.2422965
Francisco Cezar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Maria Eduarda Cavalcanti Souza, Rommel Mario Rodríguez Burbano
{"title":"The role of CLDN18.2 in gastric cancer prognosis: a systematic review and meta-analysis.","authors":"Francisco Cezar Aquino de Moraes, Luis Eduardo Rodrigues Sobreira, Maria Eduarda Cavalcanti Souza, Rommel Mario Rodríguez Burbano","doi":"10.1080/1354750X.2024.2422965","DOIUrl":"10.1080/1354750X.2024.2422965","url":null,"abstract":"<p><strong>Background: </strong>Gastric cancer (GC) is a major global cause of cancer mortality, with a median overall survival of just 12 months. CLDN18.2, a specific isoform of Claudin18 normally expressed in the gastric mucosa, has emerged as a potential therapeutic target and prognostic biomarker due to its exposure on the surface of tumor cells following malignant transformation. This exposure allows CLDN18.2's extracellular loops to bind monoclonal antibodies, presenting new opportunities for targeted therapy and improved prognostic assessment.</p><p><strong>Methods: </strong>A comprehensive search of PubMed, EMBASE, Cochrane Library, and Web of Science databases was conducted for studies that addressed the correlation of CLDN18.2 with: (1) Progression-free survival (PFS) and (2) Overall Survival (OS). Hazard ratio (HR) and odds ratio (OR) with 95% confidence intervals (CIs) were calculated using a fixed-effects model. Heterogeneity was examined with <i>I</i><sup>2</sup> statistics. <i>P</i> values of ≤ 0.05 were considered statistically significant. Statistical analyses were performed using RStudio, version 4.2.3.</p><p><strong>Results: </strong>A total of 15 studies encompassing a total of 4,085 patients were included. There were 2,691 (65.8%) male and 1,394 (34.2%) female patients. In the histologic GC analysis, there were 1,582 (38.7%) patients that had intestinal type and 1,280 (31.3%) with diffuse type. Patients with CLDN18.2 negative status exhibited a non-significant trend towards prolonged PFS (HR: 1.25; 95% CI: 0.98-1.61; <i>p</i> = 0.07; <i>I</i><sup>2</sup> = 18%) and a significant prolonged OS (HR: 1.20; 95% CI: 1.07-1.34; <i>p</i> < 0.01; <i>I</i><sup>2</sup> = 37%) when compared to CLDN18.2-positive patients.</p><p><strong>Conclusion: </strong>Our findings establish CLDN18.2 as a robust negative prognostic indicator for overall survival in GC patients. While its impact on PFS was not statistically significant, the association with OS suggests CLDN18.2 may serve as a marker for complex biological processes underlying tumor advancement.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"528-538"},"PeriodicalIF":2.0,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142494167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Usability of presepsin, calprotectin, and interleukin 6 in the diagnosis of acute appendicitis.","authors":"Emine Ozdal, Fatma Tortum, Esra Laloglu, Esra Egilmez, Kamber Kasali","doi":"10.1080/1354750X.2024.2415077","DOIUrl":"10.1080/1354750X.2024.2415077","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate presepsin, calprotectin, and interleukin-6 levels together in terms of their utility in the diagnosis of acute appendicitis and distinguishing complicated acute appendicitis cases. In addition, it was attempted to identify a biomarker that would be most useful in diagnosing acute appendicitis.</p><p><strong>Methods: </strong>This study was conducted prospectively at the emergency department of a tertiary hospital. Patients diagnosed with AA from July 3, 2023, through January 1, 2024, were evaluated. 45 patients with acute appendicitis and 45 healthy volunteers were included in the study. Presepsin, calprotectin, and interleukin-6 levels were measured in both groups and subjected to statistical analyses.</p><p><strong>Results: </strong>To ensure equality between the two groups participating in the study, 17 female and 28 male patients were included in each group. The presepsin, calprotectin, and interleukin-6 levels of the patients with appendicitis were significantly higher than those of the healthy group (<i>p</i> < 0.001 for all). However, presepsin, calprotectin, and interleukin-6 were not significant parameters in differentiating between complicated and uncomplicated appendicitis (<i>p</i> = 0.493, <i>p</i> = 0.202, and <i>p</i> = 0.448, respectively).</p><p><strong>Conclusion: </strong>Presepsin, calprotectin, and interleukin-6 levels may be useful in diagnosing acute appendicitis but would be insufficient in identifying complicated cases.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"479-484"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142406000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-31DOI: 10.1080/1354750X.2024.2418579
Mingfang Huang, Xiuming Huang, Liang Li
{"title":"ERH is a prognostic biomarker associated with immune cell infiltration in lung cancer.","authors":"Mingfang Huang, Xiuming Huang, Liang Li","doi":"10.1080/1354750X.2024.2418579","DOIUrl":"10.1080/1354750X.2024.2418579","url":null,"abstract":"<p><strong>Introduction: </strong>The enhancer of rudimentary homolog (ERH) is significant in cancers, but its role in lung cancer is understudied.</p><p><strong>Methods: </strong>We divided lung cancer patients into high and low ERH expression groups based on tumour tissue levels. Using the log-rank test, we analysed the correlation between ERH expression and patient prognosis. The effects of high ERH expression on lung cancer cell proliferation, migration, and invasion were assessed using CCK8, EDU, transwell, and wound healing assays.</p><p><strong>Results: </strong>ERH expression was significantly higher in cancerous versus normal lung tissue (<i>p</i> < 0.05), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Patients with high ERH expression had worse overall survival (HR = 1.37, <i>p</i> = 2.5 × 1 0 <sup>-7</sup>) and first progression survival (HR = 1.38, <i>p</i> = 0.00065) in lung cancer. However, while high ERH expression predicts an unfavourable prognosis in LUAD, it does not hold true for LUSC. Furthermore, knockdown of ERH inhibited lung cancer cell proliferation, migration, and invasion. ERH expression was linked to immune cell infiltration. High ERH expression in LUAD and LUSC samples correlated with higher CD8 T cell, T cells CD4 memory activated, and M1 macrophages abundance, while low ERH expression correlated with higher T cells CD4 memory resting abundance.</p><p><strong>Conclusion: </strong>Upregulation of ERH in lung cancer tissue is associated with poor prognosis and immune cell infiltration.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"466-478"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-17DOI: 10.1080/1354750X.2024.2415072
Hanan Safwat Salah Elden Hassan, Walaa A Moselhy, Marwa A Ibrahim, Ayman H Zaki, Fatma Khalil, Eman I Hassanen, Doaa R I Abdel-Gawad
{"title":"Exosomal therapy mitigates silver nanoparticles-induced neurotoxicity in rats.","authors":"Hanan Safwat Salah Elden Hassan, Walaa A Moselhy, Marwa A Ibrahim, Ayman H Zaki, Fatma Khalil, Eman I Hassanen, Doaa R I Abdel-Gawad","doi":"10.1080/1354750X.2024.2415072","DOIUrl":"10.1080/1354750X.2024.2415072","url":null,"abstract":"<p><strong>Introduction: </strong>Our investigation aims to appraise the neuroprotective impact of Bone Marrow-Mesenchymal Stem Cells (BM-MSCs) derived exosomes against Ag NPs-inducing neurotoxicity in rats.</p><p><strong>Materials and methods: </strong>Twenty-four albino rats were divided into 3 groups. Group I (control negative), Group II (intraperitoneally injected with Ag NPs for 28 days, whereas Group III (intraperitoneally injected with Ag NP and BM-MSCs derived exosomes.</p><p><strong>Results: </strong>There was a marked elevation of Malondialdehyde (MDA) along with a reduction of brain antioxidants, Gamma-aminobutyric acid (GABA) and Monoamine Oxidase (MAO) in the Ag NPs receiving group. Ag NPs upregulated c-Jun N-terminal Kinases (JNK) genes and c-Myc and downregulated the tissue inhibitors of metalloproteinases (TIMP-1) and Histone deacetylase 1 (HDAC1) genes. Otherwise, the co-treatment of BM-MSCs derived exosomes with Ag NPs could markedly increase the rat's body weight, activity and learning while, decreasing anxiety, restoring all the toxicological parameters and improving the microscopic appearance of different brain areas.</p><p><strong>Conclusion: </strong>BM-MSCs-derived exosomes downregulated both apoptotic and inflammatory mediators and upregulated the antiapoptotic genes. BM-MSCs-derived exosomes exhibit a great therapeutic effect against the neurotoxic effects of Ag NPs.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"442-458"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-17DOI: 10.1080/1354750X.2024.2415463
Hongsheng Wu, Biling Liao, Tengfei Ji, Jianbin Huang, Keqiang Ma, Yumei Luo
{"title":"Diagnostic value of CRP for predicting the severity of acute pancreatitis: a systematic review and meta-analysis.","authors":"Hongsheng Wu, Biling Liao, Tengfei Ji, Jianbin Huang, Keqiang Ma, Yumei Luo","doi":"10.1080/1354750X.2024.2415463","DOIUrl":"10.1080/1354750X.2024.2415463","url":null,"abstract":"<p><strong>Background: </strong>C-reactive protein (CRP) is a pentameric protein commonly used as a biomarker of inflammation or stress response which can be obtained during routine blood tests. Therefore, we conducted a systematic review and meta-analysis to explore its ability to predict the severity of acute pancreatitis (AP). This meta-analysis was registered in the PROSPERO system (registration number: CRD42022353769).</p><p><strong>Methods: </strong>41 studies with 6156 cases of acute pancreatitis, retrieved from PubMed, Cochrane Library, Springer, and Embase databases, were incorporated. We calculated the pooled estimates for predicting the severity of acute pancreatitis based on CRP levels. We also calculated the combined negative likelihood ratio (NLR), combined positive likelihood ratio (PLR) and combined diagnostic odds ratio (DOR) using a bivariate mixed model. Sensitivity analysis was used to examine the robustness of the results. Factors associated with heterogeneity were identified by meta-regression analysis. A summary operating characteristic (SROC) curve was generated to assess the diagnostic value of CRP in predicting severe acute pancreatitis. Fagan's test was used to calculate likelihood ratios and post-test probabilities, and publication bias was gauged by asymmetry tests.</p><p><strong>Results: </strong>SROC analysis yielded an AUC of 0.85 (95%CI: 0.81-0.88) with a sensitivity of 0.76 (95%CI: 0.69-0.83) and specificity of 0.79 (95%CI: 0.74-0.83). The combined NLR, PLR and DOR were 0.30 (0.23-0.40), 3.66 (2.94-4.55) and 12.19 (8.05-18.44) respectively. Sensitivity analysis demonstrated the stability of our results after omitting any study. Finally, meta-regression analysis indicated that the description of the reference test, prospective design, blinding method and spectrum of the disease could account for heterogeneity in this meta-analysis.</p><p><strong>Conclusion: </strong>CRP has significant value as a biomarker for assessing AP severity. Besides, other parameters such as patient history, physical signs, and imaging should be considered to determine disease severity.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"494-503"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457154","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-23DOI: 10.1080/1354750X.2024.2411346
Orcione Ferreira Guimarães Júnior, Gabriel Ledo Pereira de Oliveira, Deborah de Farias Lelis, Thaís de Oliveira Faria Baldo, Marcelo Perim Baldo, Sérgio Henrique Sousa Santos, João Marcus Oliveira Andrade
{"title":"Expression levels of ACE and ACE2 in the placenta and white adipose tissue of lean and obese pregnant women.","authors":"Orcione Ferreira Guimarães Júnior, Gabriel Ledo Pereira de Oliveira, Deborah de Farias Lelis, Thaís de Oliveira Faria Baldo, Marcelo Perim Baldo, Sérgio Henrique Sousa Santos, João Marcus Oliveira Andrade","doi":"10.1080/1354750X.2024.2411346","DOIUrl":"10.1080/1354750X.2024.2411346","url":null,"abstract":"<p><strong>Background: </strong>This study evaluated the expression of ACE and ACE2 in the placenta and white adipose tissue in lean and obese women, and correlated their levels with anthropometric, clinical, and laboratory parameters, and tissue count of inflammatory cells.</p><p><strong>Methods: </strong>A cross-sectional analytical study was performed with 49 pregnant women and their respective newborns. Samples of placenta and adipose tissue were used for measuring mRNA expression for ACE and ACE2 through qRT-PCR. Inflammatory cell counting was performed through conventional microscopy.</p><p><strong>Results: </strong>An increase in ACE expression and a decrease in ACE2 were observed in the placenta and adipose tissue of women with obesity. ACE2 levels showed a negative correlation with pre-pregnancy BMI and total cholesterol.</p><p><strong>Conclusion: </strong>Maternal obesity can modulate the expression of RAS components in the placenta and white adipose tissue, with ACE2 correlated with pre-pregnancy BMI and total cholesterol.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"434-441"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-10DOI: 10.1080/1354750X.2024.2410238
Ye Zhang, Xian Chen, Haike Du, Min Zhao, Xiaoming Jiang, Yingmin Ma
{"title":"Association between toxicity-index of diquat and in-hospital mortality in patients with acute diquat poisoning: a retrospective cohort study.","authors":"Ye Zhang, Xian Chen, Haike Du, Min Zhao, Xiaoming Jiang, Yingmin Ma","doi":"10.1080/1354750X.2024.2410238","DOIUrl":"10.1080/1354750X.2024.2410238","url":null,"abstract":"<p><strong>Background: </strong>This study investigates the impact of diquat toxicity levels on in-hospital mortality rates among patients with acute diquat poisoning. It aims to clarify the relationship between diquat toxicity scores and the likelihood of death during hospitalization.</p><p><strong>Methods: </strong>A retrospective cohort study was conducted on 98 individuals with acute diquat poisoning. Data on post-ingestion time, initial diquat plasma concentration, and clinical outcomes were systematically collected for all participants. The toxicity-index of diquat was calculated based on post-ingestion time and initial diquat plasma concentration. Logistic regression analysis was utilized to assess the association between the toxicity-index of diquat and in-hospital mortality rates, adjusting for potential confounding variables such as age, comorbidities, and treatment interventions.</p><p><strong>Results: </strong>The study found that the overall prevalence of in-hospital mortality was 34.7%, with 58.2% in males. The multivariable-adjusted regression coefficient for in-hospital mortality associated with the toxicity-index was 1.09, with a 95% confidence interval (CI) of 1.01-1.17. Subsequent exploratory subgroup analysis indicated that there were no significant interactions (all <i>p</i> values for interaction were >0.05).</p><p><strong>Conclusions: </strong>The study found that higher diquat toxicity-index values correlate with increased in-hospital mortality in acute diquat poisoning cases, indicating that the toxicity-index could be a useful biomarker for assessing mortality risk.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"427-433"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-18DOI: 10.1080/1354750X.2024.2415073
Aryan Shah, Yu Ding, David Walji, Gabriel A Rabinovich, Marc Pelletier, Mohammad El-Diasty
{"title":"The prognostic utility of galectin-3 in patients undergoing cardiac surgery: a scoping review.","authors":"Aryan Shah, Yu Ding, David Walji, Gabriel A Rabinovich, Marc Pelletier, Mohammad El-Diasty","doi":"10.1080/1354750X.2024.2415073","DOIUrl":"10.1080/1354750X.2024.2415073","url":null,"abstract":"<p><strong>Objective: </strong>To review the utility of galectin-3 (Gal-3) as a biomarker for postoperative adverse outcomes in patients undergoing cardiac surgery.</p><p><strong>Method: </strong>This review was conducted in compliance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Electronic database search was conducted in October 2023. Studies that measured pre- and/or postoperative plasma Gal-3 levels in adult patients undergoing cardiac surgery were included. Primary outcomes included postoperative morbidity and mortality.</p><p><strong>Results: </strong>Out of 391 studies screened, eight studies met the inclusion criteria. Two of the three studies showed that preoperative plasma levels of Gal-3 were associated with acute kidney injury (AKI) after cardiac surgery. Two of the three studies reported a significant increase in preoperative Gal-3 levels in patients who developed postoperative atrial fibrillation (POAF). The addition of Gal-3 to the EuroSCORE II model was found to statistically improve the prediction of both AKI and POAF. Three of the five studies suggested that Gal-3 levels can predict postoperative mortality. Finally, one study suggested that lower preoperative Gal-3 levels was associated with a higher likelihood of achieving left ventricular reverse remodeling (LVRR) after surgery.</p><p><strong>Conclusions: </strong>Gal-3 may play a promising role in predicting adverse outcomes in patients undergoing cardiac surgery. The addition of Gal-3 to clinical risk prediction scores may improve their discriminatory power in this group of patients. Future studies are warranted to justify its incorporation into routine clinical practice.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"485-493"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-18DOI: 10.1080/1354750X.2024.2415078
Dmitry A Zinovkin, Hongbo Wang, Zhicheng Yu, Qian Zhang, Yang Zhang, Sitian Wei, Ting Zhou, Qi Zhang, Jun Zhang, Eldar A Nadyrov, Abdullah Farooq, Yulia Lyzikova, Ilya V Vejalkin, Irina I Slepokurova, Md Zahidul Islam Pranjol
{"title":"The vasculogenic mimicry, CD146<sup>+</sup> and CD105<sup>+</sup> microvessel density in the prognosis of endometrioid endometrial adenocarcinoma: a single-centre immunohistochemical study.","authors":"Dmitry A Zinovkin, Hongbo Wang, Zhicheng Yu, Qian Zhang, Yang Zhang, Sitian Wei, Ting Zhou, Qi Zhang, Jun Zhang, Eldar A Nadyrov, Abdullah Farooq, Yulia Lyzikova, Ilya V Vejalkin, Irina I Slepokurova, Md Zahidul Islam Pranjol","doi":"10.1080/1354750X.2024.2415078","DOIUrl":"10.1080/1354750X.2024.2415078","url":null,"abstract":"<p><p>The microvessel compartment is crucial in the tumour microenvironment of endometrioid adenocarcinoma (EA). This study investigated the role of vasculogenic mimicry (VM), CD146, and CD105 microvessel density in the clinical prognosis of EA. A total of 188 EA cases were analyzed, with VM channels and microvessels detected using PAS/CD31, CD146, and CD105 staining. Mann-Whitney and Fisher exact tests were used to compare the study groups according to the evaluated criteria. ROC analysis included determination of the confidence interval (CI) and area under the ROC curve. The Mantel-Cox test was used to analyze progression-free survival. Multivariate Cox proportional hazard analysis was performed using stepwise regression. Results showed that VM channels and CD146 and CD105 microvessels were significantly higher (<i>p</i> < 0.0001) in cases with unfavourable prognosis. Univariate survival analysis highlighted the significant role of these factors in progression-free survival, while multivariate Cox analysis identified VM and CD146+ vessels as predictive factors. This study demonstrates, for the first time, that VM, CD146, and CD105-positive vessels are involved in EA prognosis, suggesting their potential as independent prognostic indicators and targets for antiangiogenic therapy. However, these findings require further validation through large-scale studies.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"459-465"},"PeriodicalIF":4.6,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142399235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
BiomarkersPub Date : 2024-11-01Epub Date: 2024-10-11DOI: 10.1080/1354750X.2024.2406520
Ping Qiao, Hua Du, Xin Guo, Mingxuan Yu, Caihong Zhang, Yingxu Shi
{"title":"Serum exosomal miR-200c is a potential diagnostic biomarker for breast cancer.","authors":"Ping Qiao, Hua Du, Xin Guo, Mingxuan Yu, Caihong Zhang, Yingxu Shi","doi":"10.1080/1354750X.2024.2406520","DOIUrl":"10.1080/1354750X.2024.2406520","url":null,"abstract":"<p><strong>Background: </strong>Breast cancer (BC) is one of the most common malignancies in women. Exosomes are widely found in body fluids and carry microRNAs (miRNAs) that reflect the biological properties of the parental cells. Our study aimed to investigate the differential expression of miR-200c in BC serum exosomes and its diagnostic value.</p><p><strong>Methodology: </strong>miRNA profiles in culture supernatant exosomes of normal mammary epithelial cells MCF-10A and BC cells (MCF-7, MDA-MB-231, MCF-7 Taxol) were examined by miRNA deep sequencing to screen for significantly differentially expressed miRNAs; Transmission electron microscopy (TEM), Nanoparticle tracking analysis (NTA), and Western blot were used to identify exosomes; qPCR was used to detect the expression level of miR-200c in cellular exosomes and serum exosomes; The efficacy of individual and combined tests of each indicator to diagnose BC was evaluated using receiver operating characteristic (ROC) curves.</p><p><strong>Results: </strong>We identified typical exosome features by TEM, NTA and Western blot, indicating successful exosome extraction. Then our miRNA sequencing results and qRT-PCR experiments showed that miR-200c was significantly down-regulated in BC cell exosomes. In addition, we divided the clinical serum samples into two cohorts according to region, and in independent cohort I, the serum exosomal miR-200c levels of BC patients were significantly lower than those of healthy controls. In cohort II, serum exosomal miR-200c expression was significantly lower in the BC group than in the control and benign breast disease (BBD) groups, whereas miR-200c expression in the BBD group was not statistically different from that in the control group. ROC analyses in both independent cohorts confirmed that serum exosomal miR-200c could differentiate between patients with and without BC disease and could be used as an early diagnostic marker for BC disease.</p><p><strong>Conclusion: </strong>Serum exosome miR-200c can be used as a potential biomarker for the diagnosis of BC, and combined with conventional serum diagnostic markers AFP, CA125 and CA153 can help to improve diagnostic efficiency.</p>","PeriodicalId":8921,"journal":{"name":"Biomarkers","volume":" ","pages":"419-426"},"PeriodicalIF":2.0,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142340643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}